Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00432146
Status:
COMPLETED
Last Update Posted:
2008-10-20
First Post:
2007-02-05
Brief Title:
Effect of Lugols Solution in the Patients With Graves Disease
Sponsor:
Istanbul University
Organization:
Istanbul University
Study Overview
Official Title:
Positive Effect of Lugols Solution on the Blood Flow and Microvessel Density of Thyroid Gland in the Patients With Graves Disease
Status:
COMPLETED
Status Verified Date:
2007-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Context Although some of endocrine surgeons administer Lugols solution to decrease thyroid gland vascularity there is still no agreement on its effectiveness
Objective The aims of this clinical trial are to evaluate thyroid blood flow and microvessel density in the patients with Graves disease according to the Lugols solution treatment preoperatively
Design Retrospective clinical trial Setting A tertiary referral center Method Thirty-six patients were randomly assigned to preoperative medication with Lugols solution Patients in group 1 n17 received Lugols solution for 10 days before surgical intervention whereas patients in group 2 n19 didnt receive it
Main Outcome Measures Blood flow through the thyroid arteries of patients with Graves disease was measured by color flow Doppler ultrasonography The microvessel density MVD was assessed immunohistochemically and Western blot analysis using the level of expression of CD-34 in thyroid tissue The thyroid glands weight and blood loss were measured in all patients
Objective The aims of this clinical trial are to evaluate thyroid blood flow and microvessel density in the patients with Graves disease according to the Lugols solution treatment preoperatively
Design Retrospective clinical trial Setting A tertiary referral center Method Thirty-six patients were randomly assigned to preoperative medication with Lugols solution Patients in group 1 n17 received Lugols solution for 10 days before surgical intervention whereas patients in group 2 n19 didnt receive it
Main Outcome Measures Blood flow through the thyroid arteries of patients with Graves disease was measured by color flow Doppler ultrasonography The microvessel density MVD was assessed immunohistochemically and Western blot analysis using the level of expression of CD-34 in thyroid tissue The thyroid glands weight and blood loss were measured in all patients
Detailed Description:
Thirty-six patients were randomly assigned to preoperative medication with Lugols solution Patients in group 1 n17 received Lugols solution for 10 days before surgical intervention whereas patients in group 2 n19 didnt receive it Blood flow through the thyroid arteries of patients with Graves disease was measured by color flow Doppler ultrasonography The microvessel density MVD was assessed immunohistochemically and Western blot analysis using the level of expression of CD-34 in thyroid tissue The thyroid glands weight and blood loss were measured in all patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None